COGT
Price
$4.02
Change
-$0.44 (-9.87%)
Updated
Apr 10 closing price
Capitalization
507.77M
32 days until earnings call
VRNA
Price
$53.93
Change
-$3.98 (-6.87%)
Updated
Apr 10 closing price
Capitalization
4.59B
19 days until earnings call
Ad is loading...

COGT vs VRNA

Header iconCOGT vs VRNA Comparison
Open Charts COGT vs VRNABanner chart's image
Cogent Biosciences
Price$4.02
Change-$0.44 (-9.87%)
Volume$2.1M
Capitalization507.77M
Verona Pharma
Price$53.93
Change-$3.98 (-6.87%)
Volume$1.01M
Capitalization4.59B
COGT vs VRNA Comparison Chart
Loading...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COGT vs. VRNA commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COGT is a Hold and VRNA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (COGT: $4.02 vs. VRNA: $53.93)
Brand notoriety: COGT and VRNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: COGT: 153% vs. VRNA: 69%
Market capitalization -- COGT: $507.77M vs. VRNA: $4.59B
COGT [@Biotechnology] is valued at $507.77M. VRNA’s [@Biotechnology] market capitalization is $4.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $263.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COGT’s FA Score shows that 0 FA rating(s) are green whileVRNA’s FA Score has 1 green FA rating(s).

  • COGT’s FA Score: 0 green, 5 red.
  • VRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, VRNA is a better buy in the long-term than COGT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COGT’s TA Score shows that 4 TA indicator(s) are bullish while VRNA’s TA Score has 4 bullish TA indicator(s).

  • COGT’s TA Score: 4 bullish, 4 bearish.
  • VRNA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, COGT is a better buy in the short-term than VRNA.

Price Growth

COGT (@Biotechnology) experienced а -24.58% price change this week, while VRNA (@Biotechnology) price change was -7.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.43%. For the same industry, the average monthly price growth was -15.00%, and the average quarterly price growth was -16.98%.

Reported Earning Dates

COGT is expected to report earnings on Aug 12, 2025.

VRNA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+2.43% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRNA($4.59B) has a higher market cap than COGT($508M). VRNA YTD gains are higher at: 16.128 vs. COGT (-48.462). VRNA has higher annual earnings (EBITDA): -138.53M vs. COGT (-271.59M). VRNA has more cash in the bank: 400M vs. COGT (287M). COGT has less debt than VRNA: COGT (17.5M) vs VRNA (123M). VRNA has higher revenues than COGT: VRNA (42.3M) vs COGT (0).
COGTVRNACOGT / VRNA
Capitalization508M4.59B11%
EBITDA-271.59M-138.53M196%
Gain YTD-48.46216.128-300%
P/E RatioN/AN/A-
Revenue042.3M-
Total Cash287M400M72%
Total Debt17.5M123M14%
FUNDAMENTALS RATINGS
COGT vs VRNA: Fundamental Ratings
COGT
VRNA
OUTLOOK RATING
1..100
5076
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
775
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
9435
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COGT's Valuation (81) in the Miscellaneous industry is in the same range as VRNA (81) in the Pharmaceuticals Other industry. This means that COGT’s stock grew similarly to VRNA’s over the last 12 months.

VRNA's Profit vs Risk Rating (5) in the Pharmaceuticals Other industry is significantly better than the same rating for COGT (77) in the Miscellaneous industry. This means that VRNA’s stock grew significantly faster than COGT’s over the last 12 months.

VRNA's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as COGT (96) in the Miscellaneous industry. This means that VRNA’s stock grew similarly to COGT’s over the last 12 months.

VRNA's Price Growth Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for COGT (94) in the Miscellaneous industry. This means that VRNA’s stock grew somewhat faster than COGT’s over the last 12 months.

VRNA's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as COGT (100) in the Miscellaneous industry. This means that VRNA’s stock grew similarly to COGT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COGTVRNA
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
86%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend about 1 month ago
84%
Bullish Trend 22 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 8 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
74%
View a ticker or compare two or three
Ad is loading...
COGT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYFCX65.68N/A
N/A
Rydex Financial Services C
PVFYX21.31N/A
N/A
Victory Pioneer Core Equity Y
OASVX11.62N/A
N/A
Optimum Small-Mid Cap Value A
DEVDX11.88N/A
N/A
Driehaus Event Driven
STEYX12.97N/A
N/A
AB International Strat Eqs Adv

COGT and

Correlation & Price change

A.I.dvisor indicates that over the last year, COGT has been loosely correlated with SPHDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if COGT jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COGT
1D Price
Change %
COGT100%
-9.87%
SPHDF - COGT
63%
Loosely correlated
N/A
ARWR - COGT
49%
Loosely correlated
-5.85%
XNCR - COGT
47%
Loosely correlated
-10.10%
ENGN - COGT
47%
Loosely correlated
-0.74%
CRNX - COGT
46%
Loosely correlated
-2.93%
More